The efficacy of drug-eluting stents measured as the late loss, percentage neointimal volume, restenosis, target lesion revascularization and major cardiac events is significantly better than that of bare metal stents. The incidence of thrombosis and aneurysms is similar. Although there is a slight increase in late apposition, this is not followed by an increase in cardiac events. Despite the ar...

Cardiol 2007;50:1305–9. 2. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193–202. 3. Togni M, Windecker S, Cocchia R, et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 2005;46:231–6. 4. Finn AV, Nakazawa G, Joner M, et al. Vascular responses to ...

The risk of stent thrombosis and restenosis with the second generation drug eluting stents remains. The bioresorbable vascular scaffold is a third generation stent and overcomes the problems associated with drug eluting metallic stents. The bioresorbable vascular scaffold completely absorbs within the coronary vessel over 3-5 years. Multiple trials in patients with non complex coronary disease ...

The development of coronary stents represents a major step forward in the treatment of obstructive coronary artery disease since the introduction of percutaneous coronary intervention. The initial enthusiasm for bare metal stents was, however, tempered by a significant incidence of in-stent restenosis, the manifestation of excessive neointima hyperplasia within the stented vessel segment, ultim...

OBJECTIVES To compare the efficacy and safety of percutaneous coronary intervention using second-generation drug-eluting stents with those of coronary artery bypass grafting among patients with multivessel disease and/or unprotected left main coronary artery disease in terms of mortality, myocardial infarction, repeat revascularization, and angina. BACKGROUND Although coronary artery disease ...

S irolimus eluting stents are associated with very low restenosis rates when deployed for single de novo native coronary lesions. These and other drug eluting stents are changing the face of interventional cardiology practice. A number of fundamental practical questions arise with the use of these novel stents, including the effects on in-stent restenosis (ISR) of overlapping stents, tandem ste...

Despite the favorable impact of drug eluting stents on stent restenosis, their long-term reliability is considered worrisome by some because of stent thrombosis. Often attributed to adverse reactions to the stent platform, both the drugs and polymer characteristics have been further advanced with current technologies. The present review discussed current drug eluting stents and new developments.

AIMS Compared with bare metal stents (BMS), early generation drug-eluting stents (DES) reduce the risk of revascularisation in patients with ST-elevation myocardial infarction (STEMI) at the expense of an increased risk of very late stent thrombosis (ST). Durable polymer coatings for controlled drug release have been identified as a potential trigger for these late adverse events and this has l...